Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Nurandociguat (BAY3283142) old tablet - SD, Nurandociguat old- SD, Nurandociguat (BAY3283142) new tablet - SD, Nurandociguat new- SD, Nurandociguat (BAY3283142) old tablet, Nurandociguat old, Nurandociguat (BAY3283142) new tablet, Nurandociguat new
Nurandociguat · 2 trials · 2 indications
The incidence of treatment-emergent adverse events will be summarized.
Cmax=Maximum observed concentration
AUC=Area under the concentration time curve
Cmax,md=Cmax after multiple dosing
AUCt,md=AUC after multiple dosing. t (Tau)=24 hours.
| Arm | Type | Description |
|---|---|---|
| Nurandociguat Arm | EXPERIMENTAL | Participants receive nurandociguat plus 0.4 mg nitroglycerin spray |
| Placebo Arm | PLACEBO_COMPARATOR | Participants receive placebo matching nurandociguat plus 0.4 mg nitroglycerin spray |
| Optional Scheme 1-3: Treatment A-B-C | EXPERIMENTAL | Treatment A: Single dose of nurandociguat old tablet taken without food. Treatment B: Single dose of nurandociguat new tablet taken without food. Treatment C: Single dose of nurandociguat new tablet taken with food. Wash-out between treatments will be at least 7 days after last study drug administration. |
| Optional Scheme 1-3: Treatment A-C-B | EXPERIMENTAL | Treatment A: Single dose of nurandociguat old tablet taken without food. Treatment C: Single dose of nurandociguat new tablet taken with food. Treatment B: Single dose of nurandociguat new tablet taken without food. Wash-out between treatments will be at least 7 days after last study drug administration. |
| Optional Scheme 1-3: Treatment B-A-C | EXPERIMENTAL | Treatment B: Single dose of nurandociguat new tablet taken without food. Treatment A: Single dose of nurandociguat old tablet taken without food. Treatment C: Single dose of nurandociguat new tablet taken with food. Wash-out between treatments will be at least 7 days after last study drug administration. |
| Optional Scheme 1-3: Treatment B-C-A | EXPERIMENTAL | Treatment B: Single dose of nurandociguat new tablet taken without food. Treatment C: Single dose of nurandociguat new tablet taken with food. Treatment A: Single dose of nurandociguat old tablet taken without food. Wash-out between treatments will be at least 7 days after last study drug administration. |
| Optional Scheme 1-3: Treatment C-A-B | EXPERIMENTAL | Treatment C: Single dose of nurandociguat new tablet taken with food. Treatment A: Single dose of nurandociguat old tablet taken without food. Treatment B: Single dose of nurandociguat new tablet taken without food. Wash-out between treatments will be at least 7 days after last study drug administration. |
| Optional Scheme 1-3: Treatment C-B-A | EXPERIMENTAL | Treatment C: Single dose of nurandociguat new tablet taken with food. Treatment B: Single dose of nurandociguat new tablet taken without food. Treatment A: Single dose of nurandociguat old tablet taken without food. Wash-out between treatments will be at least 7 days after last study drug administration. |
| Optional Scheme 4-5 | EXPERIMENTAL | Participants will receive nurandociguat new tablet for 7 days at a lower starting dose. Afterwards, there will be up titration to a higher dose for 11 days (nurandociguat old tablet for 5 days followed by PK analysis of old tablet formulation without food at steady state after 5 days; nurandociguat new tablet for 6 days followed by PK analysis of new tablet formulation without food at steady state after 5 days and with food after 6 days). |
| Name | Type | Description |
|---|---|---|
| Nitroglycerin spray | DRUG | 0.4 mg sublingual spray |
| Nurandociguat | DRUG | Tablet, oral |
| Placebo | DRUG | Tablet matching nurandociguat, oral |
| Nurandociguat (BAY3283142) old tablet - SD | DRUG | Single dose (SD) in treatment A. |
| Nurandociguat (BAY3283142) new tablet - SD | DRUG | Single dose (SD) in treatment B and C. |
| Nurandociguat (BAY3283142) old tablet | DRUG | High dose once daily for 5 days. |
| Nurandociguat (BAY3283142) new tablet | DRUG | Low dose once daily for 7 days, high dose once daily for 6 days. |
Inclusion Criteria: * Participant must be 40 to 80 years of age inclusive at the time of signing the informed consent * Participants with stable CAD defined by coronary artery stenosis in any of the 3 main coronary vessels greater than 50 percent documented by coronary angiography within the last 3...
Top 20 of 31 competitors
Nurandociguat is an investigational small molecule drug developed by Bayer AG. It is being studied in Phase 1 clinical trials for chronic kidney disease and stable coronary artery disease. It is also known by the code BAY3283142 and has been formulated as both an older and a newer tablet for study.
Nurandociguat is being studied for chronic kidney disease and stable coronary artery disease. One Phase 1 trial examines how a new Nurandociguat tablet is absorbed compared with an older tablet and how food affects absorption in chronic kidney disease. Another evaluates its safety alongside nitroglycerin in stable coronary artery disease.
Nurandociguat is developed by Bayer AG, which trades under the ticker BAYRY. Bayer is the sponsor of the Phase 1 studies evaluating the drug in chronic kidney disease and stable coronary artery disease.
Nurandociguat is in Phase 1 clinical development. It is investigational and has not been approved for any indication. The Phase 1 program includes a completed absorption study in chronic kidney disease and a planned safety study in stable coronary artery disease.
Nurandociguat has been studied in NCT07722585, a completed Phase 1 trial in Germany with 16 healthy volunteers comparing an old and a new Nurandociguat tablet and the effect of food. A second Phase 1 trial, NCT07431294, will assess nitroglycerin safety with Nurandociguat in stable coronary artery disease in Bulgaria and Germany.
Yes. Nurandociguat is also known by the development code BAY3283142. Trial listings also refer to formulation variants such as Nurandociguat old tablet, Nurandociguat new tablet, and their SD versions, which describe different tablet forms of the same investigational compound studied by Bayer.